Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1561-1580 of 3,900 trials

Schizophrenia Spectrum Disorders: Oxytocin Treatment Study

We are investigating whether intranasal oxytocin can enhance social skills and functioning in individuals with schizophrenia spectrum disorders. This study compares oxytocin to a placebo alongside standard psychosocial treatment.

Schizophrenia6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Advanced Solid Tumors: Datopotamab Deruxtecan Study

We are studying a new treatment for patients with advanced or metastatic solid tumors to see how well it works and its safety when used alone or with other cancer drugs.

Various Types of CancerEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Frontotemporal Dementia: AVB-101 Treatment Study

We are testing a new treatment called AVB-101 for individuals with frontotemporal dementia due to specific genetic mutations. The study aims to assess its safety and early effects on symptoms.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Type 1 Diabetes: Sotagliflozin for Kidney Health

We are investigating whether sotagliflozin can improve kidney oxygen levels in people with type 1 diabetes and chronic kidney disease. This study aims to understand its effects over three months of treatment.

Type 1 Diabetes with Kidney Complications6-12 monthsEfficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyInternal MedicineNephrology

Metastatic FAP-Positive Solid Tumors: [177Lu]Lu-OncoFAP-23

We are testing a new radioactive treatment for patients with metastatic FAP-positive solid tumors. The study looks at its safety and early signs of effectiveness, both alone and with another therapy.

Advanced FAP-positive TumorsSafety phase (I)Oncology

Preventing Opioid-Induced Constipation in Advanced Cancer Patients

We are comparing two laxatives to see which one better prevents constipation in patients with advanced cancer starting opioid pain treatment. This study will also assess quality of life and side effects.

Advanced Cancer≤3 monthsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOncology

ILUVIEN® Eye Implant for Children with Uveitis

We are studying the safety and effectiveness of the ILUVIEN® eye implant in children aged 6 to under 18 with recurrent non-infectious uveitis. This research aims to understand how well the implant works and any possible side effects.

Posterior Uveitis>2 yearsConfirmation phase (III)Monitoring phase (IV)No PlaceboStandard MedicinesCost ReimbursementOphthalmologyPediatrics

Volrustomig for Advanced Non-Small Cell Lung Cancer

We are studying the safety and effectiveness of volrustomig combined with chemotherapy and other drugs for patients with advanced or metastatic non-small cell lung cancer. This research aims to find better treatment options for this condition.

Non-small Cell Lung CancerSolid TumorsSQ, NSQ NSCLCEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cancer Treatment: PET Tracers and T Cell Activity

We are studying how two PET tracers relate to T cell changes in cancer patients before surgery. This research may help us understand T cell activation and its impact on tumor response.

Breast CancerEsophageal CancerMelanoma3-6 monthsEfficacy phase (II)Confirmation phase (III)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Soft-Tissue Sarcoma: Intensified Chemotherapy Study

We are investigating whether adding extra chemotherapy cycles helps high-risk patients with resectable soft-tissue sarcomas have better outcomes after surgery. This study compares the effects of different chemotherapy regimens on survival rates.

Resectable Non-Metastatic Soft-Tissue Sarcoma>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Atezolizumab with EIK10001 and Radiation

We are studying a new treatment combining atezolizumab, EIK10001, and radiation for patients with advanced solid tumors like pancreatic cancer and triple-negative breast cancer. This trial aims to evaluate how well this combination works in controlling cancer.

Metastatic Solid Tumors>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesInternal MedicineOncology

Advanced Sarcomas: Pembrolizumab and Cabozantinib Study

We are investigating the effects of a combination of pembrolizumab and cabozantinib in patients with advanced sarcomas. The goal is to see if this treatment can help prevent disease progression and improve overall outcomes.

Advanced Metastatic Sarcomas>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Advanced Sarcoma: Bintrafusp Alfa and Doxorubicin

We are studying a new treatment combining Bintrafusp alfa with doxorubicin for patients with advanced sarcoma. The goal is to see if this combination improves tumor response and safety compared to standard treatments.

Soft-Tissue Sarcomas>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Colorectal Cancer: RO7198457 Treatment Study

We are comparing a new treatment called RO7198457 to watchful waiting in patients with high-risk, resected Stage II and Stage III colorectal cancer. The goal is to see if the new treatment can help prevent cancer recurrence better than simply monitoring.

Stage II/Stage III Rectal Cancer or Stage II (High Risk)/Stage III Colon Cancer>2 yearsEfficacy phase (II)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Tardive Dyskinesia: Safety Study of ADE513

We are testing a new medication for people with moderate to severe tardive dyskinesia to see how safe it is for long-term use. The study will also look at its long-term effects on managing symptoms.

Tardive Dyskinesia1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyPsychiatry

LB-208 for Relapsed Solid Tumors and Lymphoma

We are testing a new medication for adults with solid tumors or lymphoma that have not responded to other treatments. This study aims to evaluate its safety and potential effectiveness.

LymphomaSolid Tumor>2 yearsSafety phase (I)Oncology

Primary Progressive Multiple Sclerosis: Adipose Stem Cell Treatment

We are exploring the use of stem cells from fat tissue to treat primary progressive multiple sclerosis. This study aims to assess the safety and potential benefits of this new approach.

Primary Progressive Multiple SclerosisSafety phase (I)Neurology

Geographic Atrophy: Pozelimab and Cemdisiran Study

We are investigating whether a new treatment combining pozelimab with cemdisiran helps slow the progression of geographic atrophy in adults. This study aims to understand its effects on vision and safety compared to cemdisiran alone.

Geographic Atrophy from Age-Related Macular Degeneration>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicineOphthalmology

Melanoma: [68Ga]Ga-FAPI PET/CT Imaging Study

We are testing a new imaging method to see how well immune checkpoint inhibitor therapy works in patients with advanced melanoma. This study aims to improve response evaluation during treatment.

Malignant Melanoma6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyOncology

Colorectal Cancer: Intermittent vs. Continuous Treatment with Panitumumab

We are studying whether an intermittent treatment of Panitumumab with FOLFIRI is as effective as continuous treatment for patients with metastatic left-sided colorectal cancer. The trial also aims to assess safety and quality of life for participants.

Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology